Daclizumab for relapsing remitting multiple sclerosis.

Area of Science:

• Neuroimmunology
• Clinical Neurology
• Pharmacology

Background:

• Daclizumab, an anti-CD25 therapy, has demonstrated potential efficacy in relapsing remitting multiple sclerosis (RRMS).
• Initial clinical trials suggest no significant safety concerns with daclizumab treatment.
• Understanding daclizumab's role in RRMS requires further investigation into its efficacy and safety profile.

Purpose of the Study:

• To evaluate the efficacy and safety of daclizumab in managing the clinical progression of relapsing remitting multiple sclerosis (RRMS).

Main Methods:

• A systematic search of multiple databases (Cochrane, MEDLINE, EMBASE) and trial registers was conducted up to February 2012.
• Randomized controlled trials (RCTs) comparing daclizumab (alone or in combination) against placebo or other treatments for RRMS were included.
• Data on efficacy, clinical progression, and adverse events were independently assessed by two reviewers.

Main Results:

• One high-quality RCT involving 230 participants treated with interferon beta was analyzed.
• No significant differences were observed in expanded disability scores or annualized relapse rates between daclizumab and placebo groups.
• High-dose daclizumab significantly reduced new or enlarged gadolinium-enhancing MRI lesions compared to placebo.

Conclusions:

• Daclizumab is well-tolerated in RRMS patients receiving interferon beta.
• High-dose daclizumab demonstrated a significant reduction in MRI lesions, but overall evidence for recommendation is insufficient.
• Further well-designed RCTs are necessary to definitively establish the efficacy and safety of daclizumab for RRMS.